PNU120596, also known as PNU-120596, is a selective inhibitor of integrin alpha4beta1 that has shown potential therapeutic applications in various inflammatory diseases and cancer. In this article, we will delve into the chemical properties of PNU120596, its health benefits, potential effects, mechanism of action, possible side effects, and dosing information.
The chemical name of PNU120596 is (S)-2-(4-(2-(5-amino-1H-pyrazol-4-yl)ethoxy)phenyl)-3-(7-azabicyclo[2.2.1]heptan-7-yl)propanoic acid. Its molecular formula is C24H30N4O3 and formula weight is 422.52 g/mol. The CAS number of PNU120596 is 501925-31-1.
Top Ten Keywords and Synonyms
PNU120596 has shown potential benefits in treating various inflammatory disorders such as multiple sclerosis, asthma, and inflammatory bowel disease. It has also been investigated for its use in cancer therapy by inhibiting tumor growth and metastasis.
PNU120596 primarily acts as an inhibitor of integrin alpha4beta1, which is involved in cell adhesion, leukocyte trafficking, and lymphocyte migration. By blocking this integrin, PNU120596 can reduce inflammation and inhibit tumor metastasis. Additionally, it has been shown to modulate extracellular matrix components such as fibronectin, further affecting cell adhesion and migration.
Integrin alpha4beta1 plays a crucial role in the regulation of leukocyte trafficking and lymphocyte migration, which are critical processes in inflammation and immune responses. PNU120596 selectively blocks the binding of integrin alpha4beta1 to its ligands, inhibiting their downstream signaling pathways. This ultimately reduces inflammation and prevents tumor metastasis.
PNU120596 has demonstrated a good safety profile in preclinical studies. However, there is limited information on its safety in humans, and further research is needed to determine its long-term safety and potential toxicities.
There is limited information on the side effects of PNU120596 in humans. However, it is expected to have minimal side effects due to its high selectivity for integrin alpha4beta1.
PNU120596 has been administered orally and intravenously in animal studies at doses ranging from 1 to 50 mg/kg. The optimal dose and route of administration for humans are unknown, and further research is needed to establish safe and effective dosing regimens.
PNU120596 is a promising inhibitor of integrin alpha4beta1 with potential therapeutic applications in various inflammatory diseases and cancer. Its mechanism of action involves blocking leukocyte trafficking and lymphocyte migration, resulting in reduced inflammation and inhibition of tumor metastasis. While it has demonstrated a good safety profile in preclinical studies, more research is needed to determine its long-term safety and potential side effects in humans. Nonetheless, PNU120596 has great potential as a novel therapeutic agent in the treatment of inflammatory disorders and cancer.